The device that saves their life is damaging their skin
Across 22 medical centers worldwide, researchers have confirmed what many families already sensed: the devices that sustain young lives with Type 1 diabetes are quietly wounding the skin that holds them. A study of nearly 1,720 children found that more than half of insulin pump users and nearly a third of glucose sensor users developed skin complications — a hidden cost of technologies otherwise considered the gold standard of care. The findings do not call for abandoning these tools, but for a more honest reckoning with what modern medicine asks of the body, and for the support structures that must follow.
- More than half of children using insulin pumps developed skin damage — irritation, eczema, scarring, or changes in fatty tissue — from the very devices designed to protect their health.
- Children with pre-existing dry skin conditions face two to five times greater risk, turning a manageable side effect into a compounding vulnerability for those already most fragile.
- When skin lesions make devices painful or unstable, children may resist wearing them or misplace them — directly undermining insulin delivery and glucose accuracy at the worst possible moment.
- In Brazil, the crisis is sharpened by inequality: insulin pumps are largely inaccessible through public healthcare, meaning families who fought hardest for access now face complications with little dermatological support.
- Medical teams are responding with site rotation, intensive hydration, and protective barriers, but prevention remains imperfect and the vigilance required falls heavily on already-burdened families.
Um estudo realizado em 22 centros médicos ao redor do mundo acompanhou quase 1.720 crianças e adolescentes e revelou um problema persistente por trás do sucesso da tecnologia moderna para diabetes: os dispositivos que mantêm esses jovens vivos estão causando danos à pele.
Mais da metade das crianças que usavam bombas de insulina desenvolveu complicações cutâneas — irritação, eczema, cicatrizes ou alterações no tecido gorduroso subcutâneo. Entre os usuários de sensores contínuos de glicose, a taxa foi menor, mas ainda expressiva: três em cada dez apresentaram algum problema. O estudo, publicado na revista Hormone Research in Paediatrics e com participação da Universidade Estadual de Campinas, é um dos mais abrangentes já realizados sobre esse efeito colateral negligenciado.
Os dispositivos em si são notáveis. Para os cerca de 95% dos participantes com diabetes tipo 1 — condição em que o organismo deixa de produzir insulina —, essas tecnologias transformaram o tratamento, permitindo controle preciso da glicemia e reduzindo episódios perigosos de hipoglicemia. Mas elas têm um custo que se manifesta na pele. A insulina possui um pH diferente do da pele humana, e sua aplicação repetida por adesivos na mesma região desencadeia inflamação. Crianças com pele seca ou condições como ceratose pilar enfrentam risco duas a cinco vezes maior de desenvolver complicações.
Os médicos ressaltam que a maioria dessas lesões é reversível e raramente evolui para infecção grave. Mas as consequências práticas são sérias: quando uma criança desenvolve feridas dolorosas no local do dispositivo, pode resistir a usá-lo ou deslocá-lo antes que a pele se recupere — comprometendo exatamente o que a tecnologia deveria garantir.
No Brasil, o cenário é agravado pela desigualdade de acesso. As bombas de insulina permanecem fora do alcance de famílias sem plano de saúde privado ou recursos para recorrer à Justiça. As complicações cutâneas acrescentam mais uma camada de dificuldade: crianças que finalmente conseguem acesso ao dispositivo podem se deparar com lesões que o tornam desconfortável ou ineficaz, sem suporte dermatológico adequado.
As equipes médicas recomendam hidratação intensa antes da inserção, rotação dos locais de aplicação e uso de barreiras protetoras. Mas a prevenção ainda é imperfeita, e o peso da vigilância recai, em grande parte, sobre as famílias. O estudo não sugere que as crianças abandonem esses dispositivos — os benefícios continuam sendo substanciais. O que ele pede é uma conversa mais honesta sobre o que essas tecnologias exigem do corpo, e um compromisso real de apoiar as crianças diante das complicações que inevitavelmente surgem.
A four-week study of nearly 1,720 children and adolescents across 22 medical centers worldwide has documented a persistent problem hiding beneath the success of modern diabetes technology: the devices that keep young patients alive are damaging their skin.
Researchers found that more than half of children using insulin pumps developed skin complications—irritation, eczema, scarring, or changes in the fatty tissue beneath the skin. Among those using continuous glucose sensors, the rate was lower but still substantial: three in ten experienced some form of skin problem. The work, published in Hormone Research in Paediatrics and including data from the State University of Campinas in São Paulo, represents one of the most comprehensive looks at this overlooked side effect.
The devices themselves are remarkable. For the roughly 95 percent of study participants with Type 1 diabetes—a condition where the body stops producing insulin entirely—these technologies have been transformative. Insulin pumps and glucose sensors allow for precise blood sugar control, reduce dangerous low-blood-sugar episodes, and free children from multiple daily injections. International medical guidelines now consider them the gold standard of care. Yet they come with a cost that plays out on the skin.
The mechanism is straightforward but difficult to prevent. Insulin is a medication with a different pH than human skin, and when injected repeatedly through an adhesive patch in the same general area, it triggers inflammation. Children whose skin is already prone to dryness or conditions like keratosis pilaris—a common roughness that makes skin more fragile—face two to five times higher risk of developing complications. The repeated insertion of a foreign object, combined with the adhesive itself and the medication's chemical properties, creates a perfect storm for lesions.
Doctors emphasize that most of these skin problems are reversible and rarely lead to serious infection. But they matter more than they might appear. When a child develops painful sores or persistent redness at the pump or sensor site, they may resist wearing the device or move it to a new location before the previous site has healed. If the device shifts or becomes loose due to skin damage, it can fail to deliver insulin properly or read glucose accurately—exactly the opposite of what the technology is designed to do. In the worst cases, poor skin health can undermine the entire treatment.
In Brazil, access to these devices is already unequal. Glucose sensors have begun to be covered by the public health system in some specialized centers, but insulin pumps remain largely out of reach for families without private insurance or the resources to pursue legal action to force coverage. The skin complications add another layer of complexity: children who finally gain access to a pump may find themselves struggling with lesions that make the device uncomfortable or ineffective, yet have no clear path to dermatological support or device alternatives.
Medical teams have developed practical strategies. Intensive skin hydration before device insertion, rotating application sites to give skin time to recover, and using protective barriers can all help. The warning signs are clear: persistent redness, intense itching, open sores, discharge, or hardening of the skin warrant immediate medical attention. But prevention remains imperfect, and the burden falls largely on families to monitor, rotate sites, and advocate for their child's skin health while managing a chronic disease that demands constant attention.
The study does not suggest that children should stop using these devices. The benefits to blood sugar control and quality of life remain substantial. Rather, it calls for a more honest conversation about what these technologies demand of the body, and a commitment to supporting children through the complications that inevitably arise.
Citações Notáveis
The devices allow for more precise blood sugar control and reduce dangerous low-blood-sugar episodes, but the indication must always be individualized, considering the child's age, clinical profile, access to technology, and family support.— Mariana Zorron, pediatric endocrinologist at Hospital de Clínicas da Unicamp
Skin lesions can compromise how well the device adheres to the body and may interfere with both insulin delivery and glucose readings, which could be inaccurate.— Mariana Zorron, pediatric endocrinologist
A Conversa do Hearth Outra perspectiva sobre a história
Why does insulin itself cause skin problems if it's meant to be injected into the body?
The issue isn't the insulin as a medicine—it's the context. When you inject it through the skin repeatedly in the same spot, the medication's chemical properties irritate the tissue. Add an adhesive patch sitting on top for days at a time, and you're creating inflammation in an area that's already under stress.
So a child could develop a sore and then what—they just move the pump to another part of their body?
In theory, yes. But if the sore is painful or the skin is damaged, the child might resist wearing the device at all, or delay putting it back on. That's when the real danger emerges: missing doses of insulin or gaps in glucose monitoring.
The study mentions that children with dry skin are at much higher risk. Can that be treated?
It can be managed—hydration, protective creams, rotating sites carefully. But it requires active attention from parents and the child. It's not something that happens automatically just because you have the device.
In Brazil, these pumps aren't covered by public insurance. Does that mean poor families can't access them at all?
Mostly, yes. Some families pursue legal action to force the government to cover the cost, but that's expensive and time-consuming. So the children who need these devices most—those with the hardest-to-control diabetes—are often the ones least likely to have access to them.
If skin problems are this common, why aren't doctors warning families about them upfront?
They should be, and increasingly they are. But for a long time, the focus was on the benefits—and they are real and significant. The skin complications were treated as minor side effects. This study is pushing the conversation toward a more complete picture.
What happens if a child develops an infection at one of these sites?
Infections are rare, but they can happen. That's when you're looking at antibiotics, possible hospitalization, and a real disruption to diabetes management. It's the worst-case scenario, but it's why monitoring the skin matters.